Acharya Prashant advocates for honest self-inquiry in spirituality, challenging superstition in all forms—old and new—and encouraging clear thinking over blind belief.

PST-611-CT1 is a first-in-human single ascending dose study that aims to establish, in six to a maximum of 12 dry AMD/GA patients, the safety profile of the drug and validate the maximal tolerated ...